Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Common Equity (2016 - 2025)

Historic Common Equity for Niagen Bioscience (NAGE) over the last 14 years, with Q3 2025 value amounting to $70.7 million.

  • Niagen Bioscience's Common Equity rose 10563.88% to $70.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.7 million, marking a year-over-year increase of 10563.88%. This contributed to the annual value of $46.1 million for FY2024, which is 6198.34% up from last year.
  • Per Niagen Bioscience's latest filing, its Common Equity stood at $70.7 million for Q3 2025, which was up 10563.88% from $64.2 million recorded in Q2 2025.
  • Niagen Bioscience's Common Equity's 5-year high stood at $70.7 million during Q3 2025, with a 5-year trough of $20.8 million in Q2 2022.
  • Over the past 5 years, Niagen Bioscience's median Common Equity value was $29.8 million (recorded in 2024), while the average stood at $35.9 million.
  • Per our database at Business Quant, Niagen Bioscience's Common Equity plummeted by 5069.53% in 2022 and then skyrocketed by 10898.17% in 2025.
  • Quarter analysis of 5 years shows Niagen Bioscience's Common Equity stood at $31.7 million in 2021, then decreased by 9.63% to $28.7 million in 2022, then dropped by 0.75% to $28.5 million in 2023, then skyrocketed by 61.98% to $46.1 million in 2024, then skyrocketed by 53.33% to $70.7 million in 2025.
  • Its last three reported values are $70.7 million in Q3 2025, $64.2 million for Q2 2025, and $55.3 million during Q1 2025.